A 3 4 7 -A 7 6 6 radiotherapy. Methods: German physicians completed a web-based medical record review for patients ≥ 18 years old who had received ≥ 1 line of systemic therapy for advanced STS (other than Kaposi's sarcoma or gastrointestinal stromal tumors) between 1/1/2005 and 20/2/2014. Physicians reported patients' clinical characteristics, treatments and outcomes. Data were summarized overall, by line of therapy, and for histological subtypes. Results: Forty physicians (primarily practicing in academic hospitals (58%) or cancer centers (28%)) provided data for 204 patients. Physicians reported that 10% (median) of the patients in their practices with advanced STS did not receive any systemic cancer-directed therapy and were thus ineligible for this study. Patients' mean age at advanced STS diagnosis was 57.4 (SD= 11.0) years, and 64% were male. The most frequent histologic subtypes were leiomyosarcoma (32%), liposarcoma (11%), and rhabdomyosarcoma (10%). Seventyseven percent of patients had stage IV STS at initial diagnosis; the remainder progressed in an average of 23 (SD= 23) months. Forty percent of patients had > 1 and 6% had > 2 lines of therapy. The five most frequent first-line chemotherapy regimens were doxorubicin (53%), doxorubicin/ifosfamide/mesna (17%), docetaxel/gemcitabine (13%), paclitaxel (4%), and dacarbazine/ifosfamide/mesna (3%); in second-line they were ifosfamide/mesna (41%), docetaxel/gemcitabine (20%), pazopanib (15%), doxorubicin (9%), and trabectedin (5%). During first-line treatment, response rate was an average of 39%, with the highest rate for patients receiving dacarbazine/ifosfamide/mesna (50%; N= 6) and the lowest rate for paclitaxel users (13%; N= 8). Median survival estimates from start of first-and second-line therapy were 13 (Q1:Q3= 8:31) and 19 (Q1:Q3= 11: Q3 not estimable) months, respectively. ConClusions: Results from this retrospective medical record review point to modest differentiation among existing therapies and a need for further improvements in advanced STS treatment options in Germany. PCN287 Skeletal-Related eveNtS (SReS) aNd ReNal FuNCtioN iN PatieNtS withSymPtomatiC multiPle myeloma (mm): ReSultS FRom Belgium, FRaNCe, geRmaNy, italy, SPaiN, SwitzeRlaNd aNd the uNited kiNgdom
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.